EC
CERO

Elequin Capital’s CERo Therapeutics CERO Stock Holding History

Elequin Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$16.4K – 549
2022
Q4 		$16.4K Hold
1
– – ﹤0.01% 422
2022
Q3 		$16K Buy
+1
New +$20.1K 0.01% 179

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Elequin Capital's CERO Position: Q1 2023 in Review

Elequin Capital sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 1 share — an estimated $16.4K sold.

Elequin Capital first reported a position in CERO in Q3 2022 and held it in 2 quarters. The position peaked at $16.4K in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

  • Elequin Capital reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Elequin Capital sold 1 CERo Therapeutics share in Q1 2023, an estimated $16.4K.
  • Elequin Capital first reported a position in CERo Therapeutics in Q3 2022 and held it in 2 quarters.
  • Elequin Capital's CERo Therapeutics position peaked at $16.4K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on Elequin Capital's 13F filing for Q1 2023, filed 11 May 2023.